Calcium channel blockers and terbutaline--a positive interaction

Area of Science:

• Pharmacology
• Respiratory Medicine
• Cardiology

Background:

• Asthma is a chronic respiratory disease characterized by airway inflammation and bronchoconstriction.
• Calcium channel blockers are primarily used for cardiovascular conditions but have potential roles in other diseases.
• Terbutaline is a common bronchodilator used in asthma management.

Purpose of the Study:

• To investigate the efficacy of nifedipine and verapamil as adjuncts to terbutaline in managing bronchial asthma.
• To assess the impact of these calcium channel blockers on pulmonary function tests (PEFR, FEF25-75%, FEV1).
• To evaluate the effect of calcium channel blockers on terbutaline-induced side effects.

Main Methods:

• A study involving patients diagnosed with bronchial asthma.
• Oral administration of nifedipine and verapamil, both alone and in combination with terbutaline.
• Measurement of pulmonary function parameters including Peak Expiratory Flow Rate (PEFR), Forced Expiratory Flow Rate (FEF25-75%), and Forced Expiratory Volume in 1 second (FEV1).
• Monitoring for side effects such as tremors and palpitations.

Main Results:

• Nifedipine and verapamil alone showed insignificant improvements in PEFR, FEF25-75%, and FEV1.
• Combination therapy with terbutaline resulted in significant increases in PEFR, FEF25-75%, and FEV1 compared to terbutaline alone.
• The calcium channel blockers notably inhibited tremors and palpitations induced by terbutaline.

Conclusions:

• Nifedipine and verapamil can enhance the bronchodilatory effects of terbutaline in asthma patients.
• These calcium channel blockers may offer a strategy to mitigate common side effects associated with terbutaline.
• Further research is warranted to explore the therapeutic potential of calcium channel blockers in asthma management.